Meloxidyl Oral Liquid | 
Meloxidyl is supplied as a liquid to add to food. It is a non-steroidal anti-inflammatory drug prescribed for dogs and cats primarily to treat musculo-skeletal problems such as osteoarthrits. Meloxidyl reduces pain and inflammation in other conditions too, and can be prescribed for any condition where these properties are likely to be of benefit.
| | | | Meloxidyl Oral Liquid | Cats » 15ml
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£10.73
(inc. VAT) | | Dogs » 10ml
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£4.93
(inc. VAT) | | Dogs » 32ml
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£11.90
(inc. VAT) | | Dogs » 100ml
• Usually ships in 24 hours, subject to prescription.
• Veterinary prescription from your vet required. (what's this?) |
£27.34
(inc. VAT) | | |
|  | Customers who purchased these items also purchased |   | | Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction 
Company name: Ceva Animal Health Ltd
Address: 90 The Broadway
Chesham
Buckinghamshire
HP5 1EG
Telephone: 01494 781510
Fax: 01494 781519
Email: cevauk@ceva.com
Website: www.ceva.com
Presentation
A pale yellow suspension containing 0.5 mg/ml meloxicam as active ingredient and 2mg/ml of sodium benzoate as a preservative.
Uses
Meloxidyl® 0.5 mg/ml oral suspension for cats is a non-steroidal anti-inflammatory drug (NSAID) for use in cats for:
- the alleviation of inflammation and pain in chronic musculo-skeletal disorders in cats
- the alleviation of mild to moderate post-operative pain and inflammation following surgical procedures, e.g. orthopaedic and soft tissue surgery.
Dosage and administration
Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight on the first day.
Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight.
Particular care should be taken with regard to the accuracy of dosing. The recommended dose should not be exceeded.
Shake well before use. To be administered orally either mixed with food or directly into the mouth.
The suspension can be given using the measuring syringe provided in the package.
The syringe fits onto the bottle and has a kg-body weight scale (from 1 kg to 10 kg) which corresponds to the maintenance dose. Thus for initiation of the therapy on the first day, twice the maintenance volume will be required.
A clinical response is normally seen within 7 days. Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent.
Avoid introduction of contamination during use.
Contra-indications, warnings, etc
Do not use in pregnant or lactating animals.
Do not use in cats suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in cats less than 6 weeks of age.
Special precautions for use in animals
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.
Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.
MELOXIDYL 0.5 mg/ml oral suspension for cats should not be used following parenteral injection of meloxicam or any other non-steroidal anti-inflammatory drugs (NSAIDs) as appropriate dosage regimens for such follow-up treatments have not been established in cats.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Adverse reactions
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. These side effects are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
Interactions
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. MELOXIDYL must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.
Overdose
Meloxicam has a narrow therapeutic safety margin in cats and clinical signs of overdose may be seen at relatively small overdose levels. In case of overdose, adverse reactions are expected to be more severe and more frequent. In the case of overdose symptomatic treatment should be initiated.
Pharmaceutical precautions
This veterinary medicinal product does not require any special storage conditions.
Use within 6 months once opened.
Legal category
POM-V
Packaging Quantities
Cardboard box containing 15 ml bottle with one measuring syringe.
The measuring syringe has a kg-body weight scale for cats (1 to 10 kg).
Further information
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
Absorption
If the animal is fasted when dosed, the maximal plasma concentrations are obtained after approximately 3 hours. If the animal is fed at the time of dosing, the absorption may be slightly delayed.
Distribution
There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins.
Metabolism
Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.
Elimination
Meloxicam is eliminated with a half-life of 24 hours. Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine. Due to the loading dose, steady state is reached after 2 days (48h).
Marketing authorisation number
EU/2/06/070/008.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Ceva Animal Health Ltd
Address: 90 The Broadway
Chesham
Buckinghamshire
HP5 1EG
Telephone: 01494 781510
Fax: 01494 781519
Email: cevauk@ceva.com
Website: www.ceva.com
Presentation
A pale yellow suspension containing 1.5 mg/ml meloxicam as active ingredient and 2 mg/ml of sodium benzoate as a preservative. For oral application to food.
Uses
Meloxidyl® is a non-steroidal anti-inflammatory drug (NSAID) for use in the alleviation of inflammation and pain in acute and chronic musculo-skeletal disorders in dogs.
Dosage and administration
To be administered orally via mixing with food. Shake well before use. Initial treatment is a single dose of 0.2 mg meloxicam/kg bodyweight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg bodyweight.
Particular care should be taken with regard to the accuracy of dosing. The suspension can be given using the measuring syringes provided in the package. The syringe fits onto the bottle and has a kg-body weight scale, which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg bodyweight). Thus, for the first day, twice the maintenance volume will be required.
The suspension could be administered using the smallest syringe for dogs less than 7 kg bodyweight (one graduation corresponding to 0.5 kg of bodyweight) or the largest syringe for dogs over 7 kg body weight (one graduation corresponding to 2.5 kg of bodyweight).
A clinical response is normally seen within 3 – 4 days. Treatment should be discontinued after 10 days if no clinical improvement is apparent.
Avoid the introduction of contaminants during use.
Contra-indications, warnings, etc
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of individual hypersensitivity to the product. Do not use in dogs less than 6 weeks of age.
Special precautions for use in animals
If side effects occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. In the case of overdose, symptomatic treatment should be initiated.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.
Adverse reactions (frequency and seriousness)
Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy have occasionally been reported. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment, but in very rare cases may be serious or fatal.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Interaction with other medicinal products and other forms of interaction
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antimicrobials and substances with high protein binding may compete for binding and thus lead to toxic effects. The product must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.
For animal use only. Keep out of reach and sight of children.
Pharmaceutical precautions
After broaching the container, the contents should be used within 6 months. If any unused product remains after this time, it should be disposed of in accordance with national regulations.
Legal category
POM-V
Packaging Quantities
High density polyethylene bottle containing 10, 32 and 100 ml, with a polyethylene syringe insert and polypropylene measuring syringes.
Further information
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In-vitro and in-vivo studies have demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
Absorption
Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 7.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.
Distribution
There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 litre/kg.
Metabolism
Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.
Elimination
Meloxicam is eliminated with a half-life of 24 hours. Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
Marketing authorisation number
EU/2/06/070/001 - Meloxidyl®. Bottle and syringe 10 ml.
EU/2/06/070/002 - Meloxidyl®. Bottle and syringe 32 ml
EU/2/06/070/003 - Meloxidyl®. Bottle and syringe 100 ml
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Ceva Animal Health Ltd
Address: 90 The Broadway
Chesham
Buckinghamshire
HP5 1EG
Telephone: 01494 781510
Fax: 01494 781519
Email: cevauk@ceva.com
Website: www.ceva.com
Presentation
A pale yellow suspension containing 1.5 mg/ml meloxicam as active ingredient and 2 mg/ml of sodium benzoate as a preservative. For oral application to food.
Uses
Meloxidyl® is a non-steroidal anti-inflammatory drug (NSAID) for use in the alleviation of inflammation and pain in acute and chronic musculo-skeletal disorders in dogs.
Dosage and administration
To be administered orally via mixing with food. Shake well before use. Initial treatment is a single dose of 0.2 mg meloxicam/kg bodyweight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg bodyweight.
Particular care should be taken with regard to the accuracy of dosing. The suspension can be given using the measuring syringes provided in the package. The syringe fits onto the bottle and has a kg-body weight scale, which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg bodyweight). Thus, for the first day, twice the maintenance volume will be required.
The suspension could be administered using the smallest syringe for dogs less than 7 kg bodyweight (one graduation corresponding to 0.5 kg of bodyweight) or the largest syringe for dogs over 7 kg body weight (one graduation corresponding to 2.5 kg of bodyweight).
A clinical response is normally seen within 3 – 4 days. Treatment should be discontinued after 10 days if no clinical improvement is apparent.
Avoid the introduction of contaminants during use.
Contra-indications, warnings, etc
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of individual hypersensitivity to the product. Do not use in dogs less than 6 weeks of age.
Special precautions for use in animals
If side effects occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. In the case of overdose, symptomatic treatment should be initiated.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.
Adverse reactions (frequency and seriousness)
Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy have occasionally been reported. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment, but in very rare cases may be serious or fatal.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Interaction with other medicinal products and other forms of interaction
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antimicrobials and substances with high protein binding may compete for binding and thus lead to toxic effects. The product must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.
For animal use only. Keep out of reach and sight of children.
Pharmaceutical precautions
After broaching the container, the contents should be used within 6 months. If any unused product remains after this time, it should be disposed of in accordance with national regulations.
Legal category
POM-V
Packaging Quantities
High density polyethylene bottle containing 10, 32 and 100 ml, with a polyethylene syringe insert and polypropylene measuring syringes.
Further information
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In-vitro and in-vivo studies have demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
Absorption
Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 7.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.
Distribution
There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 litre/kg.
Metabolism
Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.
Elimination
Meloxicam is eliminated with a half-life of 24 hours. Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
Marketing authorisation number
EU/2/06/070/001 - Meloxidyl®. Bottle and syringe 10 ml.
EU/2/06/070/002 - Meloxidyl®. Bottle and syringe 32 ml
EU/2/06/070/003 - Meloxidyl®. Bottle and syringe 100 ml
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Ceva Animal Health Ltd
Address: 90 The Broadway
Chesham
Buckinghamshire
HP5 1EG
Telephone: 01494 781510
Fax: 01494 781519
Email: cevauk@ceva.com
Website: www.ceva.com
Presentation
A pale yellow suspension containing 1.5 mg/ml meloxicam as active ingredient and 2 mg/ml of sodium benzoate as a preservative. For oral application to food.
Uses
Meloxidyl® is a non-steroidal anti-inflammatory drug (NSAID) for use in the alleviation of inflammation and pain in acute and chronic musculo-skeletal disorders in dogs.
Dosage and administration
To be administered orally via mixing with food. Shake well before use. Initial treatment is a single dose of 0.2 mg meloxicam/kg bodyweight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg bodyweight.
Particular care should be taken with regard to the accuracy of dosing. The suspension can be given using the measuring syringes provided in the package. The syringe fits onto the bottle and has a kg-body weight scale, which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg bodyweight). Thus, for the first day, twice the maintenance volume will be required.
The suspension could be administered using the smallest syringe for dogs less than 7 kg bodyweight (one graduation corresponding to 0.5 kg of bodyweight) or the largest syringe for dogs over 7 kg body weight (one graduation corresponding to 2.5 kg of bodyweight).
A clinical response is normally seen within 3 – 4 days. Treatment should be discontinued after 10 days if no clinical improvement is apparent.
Avoid the introduction of contaminants during use.
Contra-indications, warnings, etc
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of individual hypersensitivity to the product. Do not use in dogs less than 6 weeks of age.
Special precautions for use in animals
If side effects occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. In the case of overdose, symptomatic treatment should be initiated.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.
Adverse reactions (frequency and seriousness)
Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy have occasionally been reported. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment, but in very rare cases may be serious or fatal.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Interaction with other medicinal products and other forms of interaction
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antimicrobials and substances with high protein binding may compete for binding and thus lead to toxic effects. The product must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.
For animal use only. Keep out of reach and sight of children.
Pharmaceutical precautions
After broaching the container, the contents should be used within 6 months. If any unused product remains after this time, it should be disposed of in accordance with national regulations.
Legal category
POM-V
Packaging Quantities
High density polyethylene bottle containing 10, 32 and 100 ml, with a polyethylene syringe insert and polypropylene measuring syringes.
Further information
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In-vitro and in-vivo studies have demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
Absorption
Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 7.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.
Distribution
There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 litre/kg.
Metabolism
Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.
Elimination
Meloxicam is eliminated with a half-life of 24 hours. Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
Marketing authorisation number
EU/2/06/070/001 - Meloxidyl®. Bottle and syringe 10 ml.
EU/2/06/070/002 - Meloxidyl®. Bottle and syringe 32 ml
EU/2/06/070/003 - Meloxidyl®. Bottle and syringe 100 ml
| 
